Enhancement of the acoustic startle response in rats by the dopamine D 1 receptor agonist SKF 82958

Meloni, Edward G.; Davis, Michael

doi:10.1007/s002130051020

Cited by 40 publications

(32 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects on baseline startle were surprising, as previous reports have shown dopamine receptor agonists to increase startle (Davis and Aghajanian, 1976;Meloni and Davis, 1999;Meloni and Davis, 2000). Decreases in baseline likely do not account for the results of Experiment 4, as the effect of apomorphine on nicotine withdrawal-potentiated startle was apparent following 50 mg/kg apomorphine, a dose that did not affect baseline startle.…”

Section: Discussionmentioning

confidence: 65%

Increased Dopamine Receptor Activity in the Nucleus Accumbens Shell Ameliorates Anxiety during Drug Withdrawal

Radke¹,

Gewirtz

2012

Neuropsychopharmacol

View full text Add to dashboard Cite

A number of lines of evidence suggest that negative emotional symptoms of withdrawal involve reduced activity in the mesolimbic dopamine system. This study examined the contribution of dopaminergic signaling in structures downstream of the ventral tegmental area to withdrawal from acute morphine exposure, measured as potentiation of the acoustic startle reflex. Systemic administration of the general dopamine receptor agonist apomorphine or a cocktail of the D1-like receptor agonist SKF82958 and the D2-like receptor agonist quinpirole attenuated potentiated startle during morphine withdrawal. This effect was replicated by apomorphine infusion into the nucleus accumbens shell. Finally, apomorphine injection was shown to relieve startle potentiation during nicotine withdrawal and conditioned place aversion to morphine withdrawal. These results suggest that transient activation of the ventral tegmental area mesolimbic dopamine system triggers the expression of anxiety and aversion during withdrawal from multiple classes of abused drugs.

show abstract

Section: Discussionmentioning

confidence: 65%

Increased Dopamine Receptor Activity in the Nucleus Accumbens Shell Ameliorates Anxiety during Drug Withdrawal

Radke¹,

Gewirtz

2012

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Our current findings are consistent with reports where there was either no effect or a decrease in startle amplitude after treatment with a D2-like agonist (Caine et al, 1995;Wan et al, 1996;RalphWilliams et al, 2003). Reports that D1-like agonists increased startle amplitude in rats (Meloni and Davis, 1999), but decreased startle responding in mice (Holmes et al, 2001;Ralph-Williams et al, 2003), suggest there may be a species difference. Our findings do not clearly support this hypothesis because we found no significant effect of R-6-Br-APB on startle amplitude in the Sprague-Dawley rats and strainspecific and inconsistent effects in the mice.…”

Section: D2 Agonist Effects On Ppi and Locomotion In Rats Versus Micementioning

confidence: 99%

Dopamine D1 and D2 Agonist Effects on Prepulse Inhibition and Locomotion: Comparison of Sprague-Dawley Rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J Mice

Ralph

Caine

2004

J Pharmacol Exp Ther

120

View full text Add to dashboard Cite

D2 receptors have been studied in relation to therapeutic uses of dopaminergic drugs, and psychomotor stimulant effects [as manifested by decreased prepulse inhibition (PPI) of startle and increased locomotor activity] are hallmark behavioral effects of D2 agonists in rats. Genetic studies with mutant mice might be useful in this line of investigation; however, recent studies suggest that mice differ from rats with respect to D2 agonist effects. Accordingly, we studied a wide range of doses of the D2-like agonist quinelorane (0.0032-5.6 mg/kg) and the D1-like agonist R-6-Br-APB [R(ϩ)-6-bromo-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide] (0.032-5.6 mg/ kg) in outbred Sprague-Dawley rats, outbred Swiss-Webster mice, and inbred 129X1/SvJ, C57BL/6J, and DBA/2J mice. Whereas the D2 agonist dose-dependently decreased PPI and increased locomotion in rats, neither of these effects was observed in outbred or inbred mice. In contrast, the D1 agonist reduced PPI and increased locomotion in SpragueDawley rats and in Swiss-Webster, 129X1/SvJ, and C57BL/6J mice. Neither agonist decreased PPI in DBA/2J mice, although PPI was increased in this strain by a D2 antagonist. Pretreatment with either the D2 antagonist eticlopride (1 mg/kg) or the D1 antagonist SCH39166 [(Ϫ)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-(1 mg/kg) prevented the PPI-disruptive effects of quinelorane in rats and R-6-Br-APB in mice, suggesting receptor interactions in both species. In summary, psychomotor stimulant effects of a D2 agonist that were robustly observed in outbred rats were absent in several outbred and inbred strains of mice. These results may have implications for the study of mutant mice to investigate genes involved in psychomotor function in humans.Prepulse inhibition (PPI) of the acoustic startle response is a cross-species phenomenon in which the startle response is reduced when the startling stimulus is preceded by a lowintensity prepulse (Graham, 1975;Hoffman and Ison, 1980). Although abundant literature exists describing the dopamine mechanisms regulating PPI in rats, there are relatively few reports describing comparable studies across different strains of mice. It has been well established in rats that D2-like agonists such as quinpirole, 7-OH-DPAT, and quinelorane reliably disrupt PPI in outbred rats (Peng et al., 1990;Caine et al., 1995;Varty and Higgins, 1998;Swerdlow et al., 2000Swerdlow et al., , 2001b, whereas effects of the D1-like agonists SKF38393 and SKF82958 were more variable and strainspecific (Peng et al., 1990;Wan et al., 1996;Swerdlow et al., 2000Swerdlow et al., , 2001b. However, in inbred C57BL6/J and 129S6/SvEv mice, the D2-like agonist quinpirole did not decrease PPI over a wide dose range (Ralph-Williams et al., 2003), whereas D1-like agonists such as SKF82958, SKF81297, and dihydrexidine robustly decreased PPI in those strains and in a hybrid F2 line of closely related strains (Holmes et al., 2001;Ralph-Williams et al., 2003). Furthermore, the mixed D1/D2 receptor agonis...

show abstract

“…The 0.5 mg/kg dose of APO yields comparable drug levels in SDH and LEH rats within forebrain regions that regulate PPI (Swerdlow et al 2002). In some studies (n=84), haloperidol (0.1 mg/kg in distilled water/lactic acid), raclopride (0.05 mg/kg in saline) and SCH 23390 (0.05 mg/kg in saline) were administered SC as pretreatments (pretreatment times 10, 5 and 15 min, respectively), based on previous studies in which these drugs and doses were demonstrated to oppose DA agonist effects on startle and PPI (Swerdlow et al 1994;Meloni and Davis 1999;cf. Geyer et al 2001).…”

Section: Experimental Animalsmentioning

confidence: 99%

Heritable differences in the dopaminergic regulation of sensorimotor gating

et al. 2003

View full text Add to dashboard Cite

show abstract

Enhancement of the acoustic startle response in rats by the dopamine D 1 receptor agonist SKF 82958

Cited by 40 publications

References 30 publications

Increased Dopamine Receptor Activity in the Nucleus Accumbens Shell Ameliorates Anxiety during Drug Withdrawal

Increased Dopamine Receptor Activity in the Nucleus Accumbens Shell Ameliorates Anxiety during Drug Withdrawal

Dopamine D1 and D2 Agonist Effects on Prepulse Inhibition and Locomotion: Comparison of Sprague-Dawley Rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J Mice

Heritable differences in the dopaminergic regulation of sensorimotor gating

Contact Info

Product

Resources

About